oncology – Page 3

Integrating Automated Radiomics with Serum Biomarkers Redefines Risk Stratification in Metastatic Castration-Resistant Prostate Cancer

By MedXY 01/13/2026

This article explores how novel automated imaging tools, combined with clinical biomarkers, enhance risk stratification in mCRPC, while also reviewing the pivotal OS data from abiraterone and enzalutamide trials that inform contemporary treatment standards.

news Oncology Otorhinolaryngology

FDG-PET-Guided Dose De-escalation: A New Standard for HPV-Positive Oropharyngeal Cancer?

By MedXY 01/11/2026

A multi-center phase II trial demonstrates that mid-treatment FDG-PET imaging can safely identify patients with HPV+ oropharyngeal cancer for radiation dose reduction, resulting in non-inferior tumor control and significantly improved quality of life.

news Oncology Otorhinolaryngology

INDUCE-3 Trial Fails to Support Feladilimab-Pembrolizumab Combination in First-Line HNSCC

By MedXY 01/11/2026

The Phase II/III INDUCE-3 trial was terminated early after the ICOS agonist feladilimab plus pembrolizumab failed to show superiority over pembrolizumab monotherapy in first-line recurrent or metastatic head and neck squamous cell carcinoma, with survival data actually favoring the control group.

news Oncology

Eribulin Demonstrates Clinical Efficacy in Taxane-Pretreated Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma

By MedXY 01/11/2026

A Phase 2 study reveals that eribulin, a non-taxane microtubule inhibitor, provides meaningful objective responses and disease stability in patients with rare vascular sarcomas, including those previously treated with taxanes.

Gastroenterology news Oncology

Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer

By MedXY 01/11/2026

A multi-center study reveals that extensive dissection of non-metastatic tumor-draining lymph nodes reduces immunotherapy efficacy in recurrent biliary tract cancer by depleting crucial reservoirs of memory T cells and dendritic cells.

news Oncology

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer

By MedXY 01/09/2026

Explore the Phase 3 TROPION-Breast01 study results, detailing how the antibody-drug conjugate datopotamab deruxtecan offers a superior alternative to standard chemotherapy in advanced HR+/HER2- breast cancer through improved progression-free survival and a manageable safety profile.

news Oncology

Improving Persistence: Dose Escalation Enhances Adjuvant Abemaciclib Tolerability in Early Breast Cancer

By MedXY 01/09/2026

The Phase II TRADE trial demonstrates that a stepwise dose escalation of abemaciclib significantly improves drug tolerability and reduces early discontinuation rates in patients with high-risk HR-positive, HER2-negative early breast cancer compared to standard initiation protocols.

news Oncology Urology

Dual Blockade of AKT and AR Pathways: Capivasertib Plus Abiraterone Significantly Extends rPFS in PTEN-Deficient mHSPC

By MedXY 01/09/2026

The CAPItello-281 trial shows that capivasertib plus abiraterone improves radiographic progression-free survival by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer, highlighting the importance of biomarker-driven therapy.

news Oncology

Advancing Adjuvant Care: Carboplatin Intensification in High-Risk Triple-Negative Breast Cancer

By MedXY 01/08/2026

The CITRINE trial demonstrates that adding adjuvant carboplatin to standard chemotherapy significantly improves survival in high-risk triple-negative breast cancer patients, primarily by preventing early recurrence.

news Oncology Public Health

High Ultra-Processed Food Consumption Linked to Increased Mortality Among Black Breast Cancer Survivors

By MedXY 01/08/2026

A longitudinal study of 1,733 Black breast cancer survivors reveals that high intake of ultra-processed foods significantly increases both breast cancer-specific and all-cause mortality, highlighting a critical modifiable risk factor for addressing racial disparities in cancer outcomes.

Gastroenterology news Oncology

Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer

By MedXY 01/08/2026

A phase 1/2 trial demonstrates the safety and clinical potential of nonengineered, multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma, highlighting durable T cell persistence and antigen spreading as key correlates of clinical benefit.

news Oncology Public Health

Industrial Food Preservatives Linked to Increased Cancer Risk: Evidence from the NutriNet-Santé Prospective Cohort

By MedXY 01/08/2026

A large-scale prospective study of over 100,000 participants identifies significant associations between specific food preservatives, including sorbates, nitrites, and nitrates, and an increased risk of overall, breast, and prostate cancers, suggesting a need for regulatory re-evaluation.

Internal Medicine news Oncology

2025 FDA Drug Approvals: A Critical Review of New Therapeutic Frontiers and Regulatory Shifts

By MedXY 01/07/2026

A comprehensive analysis of the 46 novel drugs approved by the FDA in 2025, highlighting breakthroughs in oncology, chronic pain, and respiratory medicine, alongside significant regulatory changes and a preview of the 2026 pipeline.

Cardiology Hematology-Oncology news

Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Ambulatory Cancer Patients

By MedXY 01/05/2026

A post hoc analysis of the AVERT trial identifies GDF-15, NT-proBNP, CRP, and hs-TnT as significant predictors for venous thromboembolism and bleeding in cancer patients, offering new tools for personalized risk stratification.

Cardiology news Oncology

Ideal Cardiovascular Health Scores Linked to 38% Lower Mortality in Cancer Survivors: Insights from the Moli-sani Study

By MedXY 01/05/2026

A longitudinal study of cancer survivors reveals that those maintaining ideal cardiovascular health, measured by the Life's Simple 7 metric, significantly reduce their risk of all-cause and cancer-specific mortality through pathways involving reduced inflammation and optimized vitamin D levels.

Diabetes & Endocrinology news Oncology

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

By MedXY 12/29/2025

A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immunotherapy increasing risk and concurrent chemotherapy appearing protective.

Hematology-Oncology news Oncology

Beyond a Symptom: Baseline Fatigue as a Clinical Biomarker for Severe and Fatal Cancer Treatment Toxicities

By MedXY 12/28/2025

A large-scale pooled analysis of 17 SWOG trials demonstrates that baseline patient-reported fatigue significantly increases the risk of severe, life-threatening, and fatal toxic effects from systemic cancer therapy, highlighting its role as a critical pretreatment risk assessment tool.

Critical Care news Oncology

Survival in Cancer Patients with ARDS: The YELENNA Study Challenges ECMO Utility in Severe Cases

By MedXY 12/27/2025

The YELENNA prospective study reveals a 73.2% 90-day mortality rate for cancer patients with ARDS. Crucially, venovenous ECMO provided no survival benefit in severe cases, prompting a re-evaluation of current clinical guidelines and goals-of-care discussions for this high-risk population.

news Oncology

Cervical Stromal Involvement and Morphology Redefine LG-ESS Prognosis: Why Radiotherapy May Not Be the Answer

By MedXY 12/25/2025

Recent studies on Low-Grade Endometrial Stromal Sarcoma (LG-ESS) identify cervical stromal involvement as a key prognostic marker and suggest that adjuvant radiotherapy offers no survival benefit, advocating for individualized, risk-adapted management.

General Surgery news Oncology

Rethinking Radical Surgery: Lobectomy Matches Total Thyroidectomy Outcomes in Intermediate-Risk PTC with Unilateral N1b Disease

By MedXY 12/24/2025

A comprehensive meta-analysis suggests that for intermediate-risk papillary thyroid carcinoma with unilateral lateral lymph node metastasis, lobectomy provides oncological outcomes comparable to total thyroidectomy, challenging the necessity of radical resection and adjuvant radioactive iodine in this cohort.